Jayme Norrie

Data science cross-industry alliance developing the clinical and analytics protocols to treat comorbid CNS and chronic disease disorders to advance scientific discovery, clinical standards of care, common algorithms, and value-based outcomes measures to lead policy.

Customers: Biotech, Pharmaceutical, Hospital, Integrated Health System, Physician, Payer, Health IT, and Patient Advocates.

Developed and executes strategy for US health industry leaders to drive healthcare reimbursement policy, care standards, and decision support system architecture for comorbid CNS conditions and chronic disease to advance simultaneous, innovative solutions for the two costliest, unmet burdens in healthcare; rapid growth of CNS disorders and comorbid chronic disease. Developed business plan and pricing model, revenue model and P&L, stakeholder and CMS reimbursement expansion strategy, multi-disciplined KOL advisory teams, data research requirements, plans, and project management, data science teams, customer targets, marketing plans, and sold cross-industry alliance memberships. Established a 12-member Board of Director recruitment plan of National leaders, with a 3-year commitment of $100,000 per year, to fund operating costs.

Delivered Results:

• Created >$100M annual client value by providing the clinical and economic evidence required by Federal and private organizations to expand reimbursement for multiple physician specialties to treat CNS and comorbid conditions.
• Reduced corporate member operating deficits >$500M by leverage existing industry leader data, technology, and personnel to execute extensive project scope requirements.
• Established a new clinical service line and integrated care model being adopted by several providers and payers.

Medical informatics start-up developing enterprise-wide integrated decision support systems, using on-demand data analytics, to increase the speed and accuracy of cross-functional, patient care, and administrative workflows.
Customers: Biotech, Pharmaceutical, Medical Device, Integrated Health System, and Payer Companies, and Patients.

Developed a business model, and product, that reduce the capital required for enterprise-wide data acquisition and analytics, while improving operational performance and innovation-to-market of scientific discoveries, clinical medicine practices, reimbursement and coverage acumen, and medically relevant patient health co-management using a subscription-based platform to perform on-demand data analytics on diverse sets of specialized data. Held executive management role, leading operations, P&L, outside investment, legal, platform and product design functionality, IP, and all early marketing and pre-sales.

Delivered Results:

• Raised $32M in non-diluted startup funding through an earmark supported by 12 Congressional members, 10 pharmaceutical Government Affairs offices, and PhRMA.
• Raised $16M in VC funding in two deals, one with a joint venture agreement for an estimated $25M in 5-year revenue.
• Awarded 2009 “30 Women to Watch” in Utah Business Magazine.

Founded in 1986, a biopharmaceutical company acquired by Shire Pharmaceuticals in 2015 for $5.2B.

Customers: Physicians, Patients, Hospitals, Federal and private payers, FDA, EMA

Led the companies first marketed product, Natpara®, to the EU market by developing global commercial strategy, cross-functional team (Marketing & Sales, Medical Affairs, Clinical Development, R&D, Regulatory, Manufacturing, Distribution, Legal, Finance), Scientific and Clinical Advisory Boards, injection pen design, product pricing, CMS reimbursement and HEOR documentation, product P&L and market forecasting, field sales planning and contracting, scientific publications, competitive positioning and product messaging, CME and conference planning, promotional mix, and Corporate Public Relations. Leveraged Big Pharma experience to lead biotech scientific discovery organization into a fully functioning manufacturing organization.

Delivered Results:

• Supported $250M up-front product licensing to Nycomed, by early EU market opening, having predicted FDA rejection.
• Designed a patented injection system, Patent #7,708,732,B2, winning numerous design awards in the EU and featured in the “Nordic Cool” show at the National Museum of Women in the Arts, Washington, DC, March 2004.
• Successfully retained Senator John Glenn, former NASA astronaut and Ohio State Senator, as a product spokesperson.

The oldest private university in Georgia.

Customers: students, Fortune 500 corporations, Department of Defense

Established a new division and revenue stream to support investment in technology transfer for Mercer’s engineering, pharmacy, medical school, and business programs, that encompassed online, military base, and corporate onsite educational / degree programs. Established a design-build strategy to accelerate parallel course design with contracted sales.

Delivered Results:

• Led and executed all customer sales and contracting of $10M first year sales with Fortune 500 and Federal customers: UPS, Delta Airlines, and Walmart for onsite professional education, and the DOD for onsite degree programs on multiple military bases, in addition to CD-based courses for mesothelioma course for lawyers sold through Red Hat.
• Amplified Sales Department accomplishments and accountability through streamlined initiatives including performance metrics, sales activity dashboards, sales pipeline, profitability targets, and ideal customer profile creation.

The seventh largest pharmaceutical company in the world.

Customers: Physicians, Hospitals, VA/DOD Formularies, Pharmacies

Central Nervous System (CNS) sales specialist launching Imitrex®, Amerge®, Lamictal®, Wellbutrin®, and Zyban® to Neurologists, Psychiatrists, and Primary Care. Accepted recruitment to Dallas region to continue education for MBA, Finance for Pfizer Senior Vice President, Strategy and Business Development position being held, instead marrying USAF Officer and following his career to Georgia.

Delivered Results:

• Recruited by CEO to add strategic value to competitive and sales strategies in preparation for Pfizer product launch for Maxalt®, competing directly with GSK’s Imitrex, for migraines.
• Contracted with DOD and VA formularies based on unique, ID card, access and high-level sales ability.
• Trained physicians (neuroscience), nurses (injection pen), and sales personnel (targeting analytics).

One-year contract sales force agreement to launch new alpha-glucosidase inhibitor, Precose®, for use in type 2 diabetes management. Outperformed full-time sales representative by 50%, while earning a 4.0 in economics.

The third largest pharmaceutical company in the world.

Customers: Physicians, Hospitals, Payers, Patients, FDA, EMA, Medical Associations, Patient and Disease Advocates, In/Out Licensing Partners, Corporate Acquirers, Government Relations

Delivered corporate and product commercialization strategy support directly to the CEO and CFO to align enterprise-wide strategic goals, streamline corporate assets, and seek new sources of income by divesting medical device divisions and increasing revenue by creating a substantial Women’s Health market, requiring in a new sales division. Advised business unit Presidents, EVP/SVP/Vice Presidents, Department Chiefs, Directors, and led nine cross-functional teams.

Commercial Strategy Leader

• Developed, led, and executed commercial strategic plans for five consecutive $1B blockbusters, from Phase II through global product launch: Procardia XL®, Norvasc®, Zithromax®, Zoloft®, Cardura®.
• Corporate and Commercial cross-functional team leadership authority across all departments and business units.
• Planned, presented, and managed product launch budgets of $40M - $75M.

VP, Corporate Strategy

• Led the quantitative and qualitative analysis of 5 medical device business units for divestiture valuation resulting in $21.04B corporate income evaluating product commercial feasibility, US and global sales projections, executive management competency, new product development, commercial / product / marketing / sales strategies.
• Developed and executed $1.5B corporate cost reduction strategy implemented across all pharmaceutical and medical device business units to share common resources, reducing operational costs and maximizing profitability.
• Developed and executed $7.5B rebate and sliding scale pricing model known today as product bundling.